174 related articles for article (PubMed ID: 20164660)
21. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Ascari E
Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
[TBL] [Abstract][Full Text] [Related]
22. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.
Kanakura Y; Shirasugi Y; Yamaguchi H; Koike M; Chou T; Okamoto S; Achenbach H; Wu J; Nakaseko C
Int J Hematol; 2018 Nov; 108(5):491-498. PubMed ID: 30121892
[TBL] [Abstract][Full Text] [Related]
23. [Anagrelide for treatment of patients with essential thrombocythaemia].
Boban A; Sertić D; Radman I; Zupancić-Salek S; Zadro R; Labar B
Lijec Vjesn; 2008; 130(5-6):141-5. PubMed ID: 18792562
[TBL] [Abstract][Full Text] [Related]
24. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
25. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F
Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
[TBL] [Abstract][Full Text] [Related]
26. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.
Gisslinger H; Buxhofer-Ausch V; Hodisch J; Radinoff A; Karyagina E; Kyrcz-Krzemień S; Abdulkadyrov K; Gerbutavicius R; Melikyan A; Burgstaller S; Hus M; Kłoczko J; Yablokova V; Tzvetkov N; Całbecka M; Shneyder T; Warzocha K; Jurgutis M; Kaplanov K; Jilma B; Schoergenhofer C; Klade C
Br J Haematol; 2019 May; 185(4):691-700. PubMed ID: 30919941
[TBL] [Abstract][Full Text] [Related]
27. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
28. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
Hernández-Boluda JC; Pereira A; Cervantes F; Gómez M; Arellano-Rodrigo E; Alvarez-Larrán A; Ferrer-Marín F; Kerguelen A; Márquez JA; Antelo ML; Besses C;
Ann Hematol; 2013 Jun; 92(6):771-5. PubMed ID: 23354997
[TBL] [Abstract][Full Text] [Related]
29. Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists.
Reilly JT
Hematology; 2009 Feb; 14(1):1-10. PubMed ID: 19154658
[TBL] [Abstract][Full Text] [Related]
30. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
31. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
Petrides PE
Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
[TBL] [Abstract][Full Text] [Related]
32. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
[TBL] [Abstract][Full Text] [Related]
33. [Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia].
Giralt M; Navas V; Hernández-Nieto L; Burgaleta C; Carbonell F; Ramírez G; Vicente V; Besses C;
Med Clin (Barc); 2009 Jun; 133(3):86-90. PubMed ID: 19501853
[TBL] [Abstract][Full Text] [Related]
34. Treatment of essential thrombocythemia in childhood.
Scherer S; Ferrari R; Rister M
Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
[TBL] [Abstract][Full Text] [Related]
35. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
36. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemia.
Besses C; Zeller W; Alvarez-Larrán A; Coll R; Troy S; Purkayastha J; Martin P; Freitag C
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):787-96. PubMed ID: 22943924
[TBL] [Abstract][Full Text] [Related]
38. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
39. Long-term use of anagrelide in young patients with essential thrombocythemia.
Storen EC; Tefferi A
Blood; 2001 Feb; 97(4):863-6. PubMed ID: 11159509
[TBL] [Abstract][Full Text] [Related]
40. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]